Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies

Heart

Volumn 92, Issue 2, 2006, Pages 190-195

  Verma, A ^a   Kilicaslan, F ^a   Martin, D O ^a   Minor, S ^a   Starling, R ^a   Marrouche, N F ^a   Almahammed, S ^a   Wazni, O M ^a   Duggal, S ^a   Zuzek, R ^a   Yamaji, H ^a   Cummings, J ^a   Chung, M K ^a   Tchou, P J ^a   Natale, Andrea ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DEVICE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART PACING; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK FACTOR; TACHYCARDIA; TREATMENT INDICATION; VALVULAR HEART DISEASE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; DEFIBRILLATORS, IMPLANTABLE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 31144431892     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.058198     Document Type: Article

References (27)

1. AVID Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus implantable defibrillators (AVID) investigators. N Engl J Med 1997;337:1576-83.
2. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
4. Anvari A, Gottsauner-Wolf M, Turel Z, et al. Predictors of outcome in patients with implantable cardioverter defibrillators. Cardiology 1998;90:180-6.
5. Dolack GL. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac arrest in Seattle, conventional versus amiodarone drug evaluation. Am J Cardiol 1994;73:237-41.
6. Grimm W, Flores BT, Marchlinski FE. Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation 1993;87:1880-8.
7. Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558-66.
8. Rankovic V, Karha J, Passman R, et al. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2002;89:1072-6.
9. Whang W, Mittleman MA, Rich DQ, et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the triggers of ventricular arrhythmias (TOVA) study. Circulation 2004;109:1386-91.
10. Reiter MJ, Fain ES, Senelly KM, et al. Predictors of device activation for ventricular arrhythmias and survival in patients with implantable pacemakers/defibrillators. CADENCE investigators. Pacing Clin Electrophysiol 1994;17:1487-98.
11. Freedberg NA, Hill JN, Fogel RI, et al. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. J Am Coll Cardiol 2001;37:1910-5.
12. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004;147:931-8.
13. Yu CM, Sanderson JE. Plasma brain natriuretic peptide-an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999;1:59-65.
14. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
15. Tapanainen JM, Lindgren KS, Makikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004;43:757-63.
16. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
17. Isnard R, Pousset F, Chafirovskaia O, et al. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 2003;146:729-35.
18. Wallen T, Landahl S, Hedner T, et al. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997;77:264-7.
19. Gibelin P. An evaluation of symptom classification systems used for the assessment of patients with heart failure in France. Eur J Heart Fail 2001;3:739-46.
20. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004;6:261-8.
21. Hansen DE, Craig CS, Hondeghem LM. Stretch-induced arrhythmias in the isolated canine ventricle: evidence for the importance of mechanoelectrical feedback. Circulation 1990;81:1094-105.
22. Zhu WX, Johnson SB, Brandt R, et al. Impact of volume loading and load reduction on ventricular refractoriness and conduction properties in canine congestive heart failure. J Am Coll Cardiol 1997;30:825-33.
23. Dogra V, Oliver R, Lapidus J, et al. Apparent protective effect of increased left ventricular wall thickness in an ICD population. J Card Fail 2003;9:412-5.
24. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9.
25. Bailey JJ, Berson AS, Handelsman H, et al. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001;38:1902-11.
26. Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the antiarrhythmics versus implantable defibrillators (AVID) trial. J Cardiovasc Electrophysiol 2003;14:940-8.
27. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.